Kura Oncology Inc (KURA)

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67...

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and...

Form 4 - Statement of changes in beneficial ownership of securities